Wednesday, May 22, 2019 Daily Archives

REGENXBIO building Maryland AAV plant to support gene therapies

by

REGENXBIO will construct a GMP facility in Maryland to produce adeno-associated viral vectors for its gene therapy programs using its NAV technology-based platform. The good manufacturing practice (GMP) plant will be integrated into REGENXBIO’s 132,000 square-foot headquarters in Rockville, Maryland, currently under construction. Financial details have not been disclosed but the manufacturing plant is expected to be operational in 2021. “The creation of this additional manufacturing capacity using our platform suspension cell culture process will allow us to more efficiently…

May 22, 2019

Thermo Fisher $50m spend to support high single-use uptake

by

Single-use adoption has gone from niche applications to standard practice in biomanufacturing says Thermo Fisher, which is expanding its disposable capabilities. Thermo Fisher has laid down plans to expand its bioproduction equipment capacity through a $50 million (€45 million) investment on the back of growing demand for its single-use bioprocess container (BPC) systems. “The majority of our 2019 investment will be across our SUT [single-use technology] network in the US, and nearly $10 million will be spent specifically at our…

May 22, 2019

WuXi scouts single-use site for Chinese vaccine joint venture

by

WuXi Biologics has formed a vaccine production division to service a $3 billion strategic partnership with an unnamed global pharma. WuXi Vaccines is a joint venture between contract development and manufacturing (CDMO) WuXi Biologics and Shanghai-based Hile Bio-Technology. The new entity has been formed to service a Letter of Intent (LOI) inked with a multinational vaccine company. The client has not been disclosed, but WuXi Biologics CEO Chris Chen told Bioprocess Insider the strategic partnership will allow the vaccine developer…

May 22, 2019